Sprint Bioscience AB (publ) (STO:SPRINT)
Sweden · Delayed Price · Currency is SEK 3.520
+0.100 (2.92%)
May 21, 2026, 12:56 PM CET
Sprint Bioscience AB Market Cap
Sprint Bioscience AB has a market cap or net worth of 360.86 million as of May 21, 2026. Its market cap has increased by 755.71% in one year.
Market Cap
360.86M
Enterprise Value
252.53M
Revenue
153.10M
Ranking
n/a
PE Ratio
4.15
Stock Price
3.52
Market Cap Chart
Since November 7, 2014, Sprint Bioscience AB's market cap has increased from 62.49M to 360.86M, an increase of 477.43%. That is a compound annual growth rate of 16.41%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 20, 2026 | 360.86M | 132.65% |
| Dec 30, 2025 | 155.11M | 40.43% |
| Dec 30, 2024 | 110.46M | -8.82% |
| Dec 29, 2023 | 121.14M | 449.78% |
| Dec 30, 2022 | 22.03M | -88.47% |
| Dec 30, 2021 | 191.05M | 17.26% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| FluoGuide | 671.96M |
| Corline Biomedical AB | 458.64M |
| Intervacc AB | 410.34M |
| Ascelia Pharma AB | 385.92M |
| Mendus AB | 350.30M |
| Isofol Medical AB | 230.75M |
| Xbrane Biopharma AB | 226.66M |
| Xintela AB | 212.73M |